Bristol Myers Squibb Dividend Raise Streak is 18 Years. Here's 1 Number That Says the Streak Will Continue.

Bristol Myers Squibb has maintained an 18-year dividend growth streak despite facing patent cliffs on flagship drugs like Eliquis. The company's $3.5 billion in planned cost savings by 2027 and a sustainable 40% payout ratio support continued dividend growth. With $10.5 billion in cash reserves, BMY appears well-positioned to maintain and grow its 4.5% dividend yield.